J&J Topamax labeling expansions
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Topiramate tablets and sprinkle capsules add indication Aug. 28 for adjunctive therapy for seizures associated with Lennox-Gastaut syndrome in patients two years and older. J&J's Topamax is the third anticonvulsant, after GlaxoSmithKline's Lamictal (lamotrigine) and Carter-Wallace's Felbatol (felbamate), indicated for Lennox-Gastaut syndrome. New labeling will also include a warning regarding acute myopia and secondary angle closure glaucoma, based on 23 reports of acute myopia/glaucoma as of Aug. 17. The company will send a "Dear Health Care Professional" letter detailing the myopia and glaucoma warning
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.